guest ::
| Home > Publications database > Early phase 18F-FET PET may help to differentiate tumor progression from treatment-related changes in glioma patients |
| Home > Publications database > Early phase 18F-FET PET may help to differentiate tumor progression from treatment-related changes in glioma patients |
| Abstract | FZJ-2026-01529 |
; ; ; ; ; ; ; ;
2025
This record in other databases:
Please use a persistent id in citations: doi:10.1055/s-0045-1804440
Abstract: Ziel/Aim: Differentiating tumor progression (TP) from treatment-related changes (TRC) in patients with suspected recurrent glioma is challenging and O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET may be used during diagnostic work up [1]. We investigated whether, in addition to standard 18F-FET PET from 20–40 min p.i., early-phase 18F-FET PET from 0–2 min p.i. may help to differentiate TP from TRC [2].Methodik/Methods: Eighty patients with glioma (WHO grades 2-4) and suspected TP underwent 18F-FET PET and were retrospectively analysed. Definitive diagnosis was achieved by histopathology or clinico-radiological follow-up (TP, n=64; TRC, n=16). Standard 18F-FET PET parameters were evaluated in the summed images from 20-40 min p.i. [3]. In addition tumor-to-brain ratios (TBR) were calculated in early-phase 18F-FET PET from 0-2 min p.i. using tumour regions-of-interest (ROI) with varying diameters (16 mm (d16); 10 mm (d10)). Receiver operating characteristic analysis was performed and the diagnostic performance to differentiate TP from TRC was assessed using standard 18F-FET PET parameters, early-phase 18F-FET PET parameters or combinations thereof.Ergebnisse/Results: Standard 18F-FET PET parameters based on summed images from 20-40 min p.i. differentiated TP from TRC with a sensitivity, specificity and accuracy of 63%, 75% and 65%, respectively. Early-phase 18F-FET PET from 0-2 min p.i. yielded a lower diagnostic performance for both ROIs (d16 ROI: sensitivity, 47%; specificity, 94%; accuracy, 56%; d10 ROI: sensitivity, 42%, specificity, 94%; accuracy, 53%). The combination of standard and early-phase 18F-FET PET increased diagnostic accuracy to differentiate TP from TRC (d16 ROI: sensitivity, 75%, specificity, 75%; accuracy, 75%; d10 ROI: sensitivity, 72%; specificity, 75%; accuracy, 73%).Schlussfolgerungen/Conclusions: The combination of early-phase and standard 18F-FET PET may help to differentiate TP from TRC in patients with gliomas.
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
